Anne C Murray

US Patent:

8603474, Dec 10, 2013

Filed:

Jan 29, 2009

Appl. No.:

12/735576

Inventors:

Gerd Ritter - New York NY, US
Beatrice Yin - New York NY, US
Anne Murray - New York NY, US
George Mark - New York NY, US
Lloyd Old - New York NY, US
Kenneth Lloyd - New York NY, US
Serhiy Souchelnytskiy - Stockholm, SE
Ivan Gout - London, GB
Valeriy Filonenko - Kviv, UA
Ramziya Kiyamova - Kviv, UA

Assignee:

Ludwig Institute for Cancer Research, Ltd. - New York NY
Institute of Molecular Biology and Genetics National Academy of Science of Ukraine - Kiev
Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

A61K 39/395
G01N 33/53
C07K 16/00
C07K 16/28
C07K 16/18

US Classification:

4241331, 4241301, 4241341, 4241391, 435 71, 5303871, 5303873, 5303879, 5303888, 5303913

Abstract:

The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

US Patent:

20110076232, Mar 31, 2011

Filed:

Sep 24, 2010

Appl. No.:

12/890029

Inventors:

Lloyd J. Old - New York NY, US
Terrance Grant Johns - Clayton, AU
Con Panousis - Melbourne, AU
Andrew Mark Scott - Kew, AU
Christoph Renner - Homburg/Saar, DE
Achim Jungbluth - New York NY, US
Elizabeth Stockert - Wien, AT
Vincent Peter Collins - Cambridge, GB
Webster K. Cavenee - Del Mar CA, US
Huei-Jen Su Huang - Rancho Santa Fe CA, US
Antony Wilks Burgess - Camberwell, AU
Edouard Collins Nice - St. Kilda, AU
Anne Murray - New York NY, US
George Mark - New York NY, US
Gerd Ritter - New York NY, US

Assignee:

LUDWIG INSTITUTE FOR CANCER RESEARCH - Abbott Park IL

International Classification:

A61K 51/10
C07K 16/28
A61K 39/395
A61P 35/00

US Classification:

424 149, 5303879, 5303873, 4241391, 4241781, 4241791, 5303891

Abstract:

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

US Patent:

20110293511, Dec 1, 2011

Filed:

Apr 1, 2011

Appl. No.:

13/078781

Inventors:

Terrance Grant Johns - Victoria, AU
Andrew Mark Scott - Victoria, AU
Gerd Ritter - New York NY, US
Achim Jungbluth - New York NY, US
Elizabeth Stockert - Wien, AT
Vincent Peter Collins - Cambridge, GB
Webster K. Cavenee - Del Mar CA, US
Huei-Jen Su Huang - Rancho Santa Fe CA, US
Antony Wilks Burgess - Victoria, AU
Edouard Collins Nice - Victoria, AU
Anne Murray - New York NY, US
George Mark - New York NY, US
Lloyd J. Old - New York NY, US
Edward B. Reilly - Libertyville IL, US
Andrew C. Phillips - Libertyville IL, US
Jonathan A. Meulbroek - Lake Bluff IL, US
Fritz G. Buchanan - Antioch IL, US
Stephen Stockert - Wien, AT

International Classification:

A61K 39/395
A61K 38/21
A61K 38/20
A61K 103/20
A61K 103/40
A61K 103/30
A61K 103/32
A61K 103/00
A61P 35/00

US Classification:

424 111, 4241391, 424 857, 424 856, 424 852

Abstract:

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

US Patent:

20110313230, Dec 22, 2011

Filed:

Apr 1, 2011

Appl. No.:

13/078764

Inventors:

Terrance Grant Johns - Victoria, AU
Andrew Mark Scott - Victoria, AU
Gerd Ritter - New York NY, US
Achim Jungbluth - New York NY, US
Elizabeth Stockert - Wien, AT
Stephen Stockert - Wien, AT
Vincent Peter Collins - Cambridge, GB
Webster K. Cavenee - Del Mar CA, US
Huei-Jen Su Huang - Rancho Sante Fe CA, US
Antony Wilks Burgess - Victoria, AU
Edouard Collins Nice - Victoria, AU
Anne Murray - New York NY, US
George Mark - New York NY, US
Lloyd J. Old - New York NY, US
Edward B. Reilly - Libertyville IL, US
Andrew C. Phillips - Libertyville IL, US
Jonathan A. Meulbroek - Lake Bluff IL, US
Fritz G. Buchanan - Antioch IL, US

International Classification:

A61N 5/00
A61K 38/19
A61P 35/00
A61K 51/00
A61K 38/21
A61K 39/395
A61K 38/20

US Classification:

600 1, 4241381, 4241331, 424 851, 424 852, 424 111, 424 856, 424 857

Abstract:

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

US Patent:

20120183471, Jul 19, 2012

Filed:

Feb 17, 2010

Appl. No.:

13/201061

Inventors:

Lloyd J. Old - New York NY, US
Constance Old - New York NY, US
Andrew Mark Scott - Victoria, AU
Gerd Ritter - New York NY, US
Achim Jungbluth - New York NY, US
Elisabeth Stockert - Wien, AT
Stephen Stockert - Wien, AT
Vincent Peter Collins - Cambridge, GB
Webster K. Cavenee - Del Mar CA, US
Huei-Jen Su Huang - Rancho Santa Fe CA, US
Antony Wilks Burgess - Camberwell, AU
Edouard Collins Nice - St. Kilda, AU
Anne Murray - New York NY, US
George Mark - New York NY, US
Terrance Grant Johns - Clayton, AU
Con Panousis - Melbourne, AU
Christoph Renner - Homburg/Saar, DE

Assignee:

LUDWIG INSTITUTE FOR CANCER RESEARCH - New York NY

International Classification:

A61K 39/395
A61P 35/00
C12N 1/19
G01N 33/574
C12N 5/10
C12N 1/21
C07K 16/30
A61K 51/00

US Classification:

424 111, 5303879, 4241391, 5303913, 5303917, 436501, 435 723, 435331, 43525233, 4352523, 4352542

Abstract:

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

US Patent:

20210032366, Feb 4, 2021

Filed:

Mar 13, 2020

Appl. No.:

16/818062

Inventors:

- Zurich, CH
Terrance Grant Johns - Clayton, AU
Con Panousis - Melbourne, AU
Andrew M. Scott - Kew East, AU
Christoph Renner - Homburg/Saar, DE
Gerd Ritter - New York NY, US
Achim Jungbluth - New York NY, US
Elisabeth Stockert - Wien, AT
Vincent Peter Collins - Cambridge, GB
Webster K. Cavenee - Del Mar CA, US
Huei-Jen Su Huang - Rancho Sante Fe CA, US
Antony Wilks Burgess - Camberwell, AU
Edouard Collins Nice - Docklands, AU
Anne Murray - New York NY, US
George Mark - New York NY, US

International Classification:

C07K 16/40
A61K 39/395
A61K 51/10
C07K 16/28
C07K 16/30
C07K 16/42
A61K 47/68
A61K 31/495

Abstract:

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

US Patent:

20180057606, Mar 1, 2018

Filed:

Jul 27, 2017

Appl. No.:

15/661864

Inventors:

- Zurich, CH
Terrance Grant Johns - Clayton, AU
Con Panousis - Melbourne, AU
Andrew M. Scott - Kew East, AU
Christoph Renner - Homburg/Saar, DE
Gerd Ritter - New York NY, US
Achim Jungbluth - New York NY, US
Elisabeth Stockert - Wien, AT
Vincent Peter Collins - Cambridge, GB
Webster K. Cavenee - Del Mar CA, US
Huei-Jen Su Huang - Rancho Sante Fe CA, US
Antony Wilks Burgess - Camberwell, AU
Edouard Collins Nice - Docklands, AU
Anne Murray - New York NY, US
George Mark - New York NY, US

International Classification:

C07K 16/40
A61K 31/495
A61K 39/395
A61K 51/10
C07K 16/30
C07K 16/42
C07K 16/28
A61K 39/00

Abstract:

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

US Patent:

20170362336, Dec 21, 2017

Filed:

May 31, 2017

Appl. No.:

15/609839

Inventors:

Gerd Ritter - New York NY, US
Beatrice Yin - New York NY, US
Anne Murray - New York NY, US
George Mark - New York NY, US
Lloyd J. Old - New York NY, US
Kenneth Lloyd - New York NY, US
Serhiy Souchelnytskiy - Stockholm, SE
Ivan Gout - London, UK
Valeriy Filonenko - Kiev, UA
Ramziya Kiyamova - Kiev, UA

International Classification:

C07K 16/30
A61K 39/00
A61K 39/395
G01N 33/574
C07K 14/47
C07K 14/705
C07K 16/18
C07K 16/28
C07K 7/08

Abstract:

The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.